☆最新提示☆ ◇600196 复星医药 更新日期：2026-03-27◇ ★本栏包括【1.最新提醒】【2.最新报道】【3.最新异动】【4.最新运作】 【1.最新简要】 ★2026年一季报将于2026年04月29日披露 ┌─────────┬────┬────┬────┬────┬────┐ ｜★最新主要指标★ ｜25-12-31｜25-09-30｜25-06-30｜25-03-31｜24-12-31｜ ｜每股收益(元) ｜ 1.2700｜ 0.9500｜ 0.6400｜ 0.2900｜ 1.0400｜ ｜每股净资产(元) ｜ 18.2523｜ 17.9853｜ 17.7491｜ 17.9400｜ 17.6920｜ ｜净资产收益率(％) ｜ 7.0300｜ 5.3000｜ 3.5800｜ 1.6100｜ 5.9000｜ ｜总股本(亿股) ｜ 26.7043｜ 26.7043｜ 26.7043｜ 26.7133｜ 26.7133｜ ｜实际流通A股(亿股) ｜ 21.1849｜ 21.1849｜ 21.1849｜ 21.1849｜ 21.1849｜ ｜限售流通A股(亿股) ｜ --｜ --｜ --｜ 0.0090｜ 0.0090｜ ├─────────┴────┴────┴────┴────┴────┤ ｜★最新分红扩股和未来事项: ｜ ｜【分红】2025年度 ｜ ｜【分红】2025年半年度 ｜ ｜【分红】2024年度 股权登记日:2025-08-01 除权除息日:2025-08-04 ｜ ｜【增发】2020年拟非发行的股票数量为12814.4927万股(预案) ｜ ｜【增发】2022年(实施) ｜ ├──────────────────────────────────┤ ｜★特别提醒: ｜ ｜★2026年一季报将于2026年04月29日披露 ｜ ├──────────────────────────────────┤ ｜2025-12-31每股资本公积:6.13 主营收入(万元):4166161.27 同比增:1.45% ｜ ｜2025-12-31每股未分利润:10.88 净利润(万元):337056.16 同比增:21.69% ｜ └──────────────────────────────────┘ 近五年每股收益对比： ┌──────┬──────┬──────┬──────┬──────┐ ｜ 年度 ｜ 年度 ｜ 三季 ｜ 中期 ｜ 一季 ｜ ├──────┼──────┼──────┼──────┼──────┤ ｜2025 ｜ 1.2700｜ 0.9500｜ 0.6400｜ 0.2900｜ ├──────┼──────┼──────┼──────┼──────┤ ｜2024 ｜ 1.0400｜ 0.7500｜ 0.4600｜ 0.2300｜ ├──────┼──────┼──────┼──────┼──────┤ ｜2023 ｜ 0.8900｜ 0.8600｜ 0.6700｜ 0.3700｜ ├──────┼──────┼──────┼──────┼──────┤ ｜2022 ｜ 1.4300｜ 0.9500｜ 0.6000｜ 0.1800｜ ├──────┼──────┼──────┼──────┼──────┤ ｜2021 ｜ 1.8500｜ 1.3900｜ 0.9700｜ 0.3300｜ └──────┴──────┴──────┴──────┴──────┘ 【2.最新报道】 【2026-03-26】复星医药子公司复宏汉霖新一代靶向CD47-SIRPα融合蛋白HLX701 完成晚期结直肠癌Ib/II期首例患者给药 2026年3月26日，复星医药子公司复宏汉霖(2696.HK)宣布，公司创新型重组人SIRP α-Fc融合蛋白注射液HLX701联合西妥昔单抗及化疗治疗晚期RAS/BRAF野生型结直 肠癌患者的Ib/II期临床研究(HLX701-CRC201)完成首例患者给药。 结直肠癌是我国乃至全球高发的恶性肿瘤。2022年，全球新发结直肠癌约192.6万 例，死亡约90.4万例，其中我国新发及死亡病例分别达51.7和24.0万例，位居恶性 肿瘤发病率的第二位，死亡率的第四位1-2。对于晚期/转移性结直肠癌，一、二线 标准治疗方案主要为基于氟尿嘧啶类的化疗药物联合抗血管生成药物(抗VEGF靶向 治疗)或抗EGFR靶向治疗。其中，西妥昔单抗(抗EGFR单抗)联合化疗是RAS/BRAF野 生型晚期结直肠癌的标准一线治疗方案之一。随着疾病进展，后线治疗选择有限且 获益仍有待提升，目前可选方案包括瑞戈非尼、呋喹替尼、TAS-102等3-7，临床亟 需更有效、可联合的治疗策略。靶向CD47-SIRPα信号通路的免疫治疗已在结直肠 癌等实体瘤和血液瘤中展开了初步临床探索，尤其联合治疗在肿瘤特定分子分型中 显示出协同治疗潜力8-9。随着新一代CD47-SIRPα靶向药物的持续升级和迭代，其 疗效及联合策略亟待在临床研究中进一步验证。 HLX701是复宏汉霖自汉康生技(HanchorBio)旗下FBD Biologics Limited(简称“F BD”)引进，并由双方依据合作协议共同推进开发的新一代SIRPα-Fc融合蛋白。该 分子是一种工程改造的人类SIRPα免疫球蛋白(IgV)结构域与人免疫球蛋白G4(IgG4 )片段可结晶(Fc)区域蛋白结合的融合蛋白，能够以高亲和力结合肿瘤细胞上的CD4 7，有效阻断抑制性CD47“别吃我”抗吞噬信号，从而促进巨噬细胞对肿瘤细胞的 吞噬作用及增强抗肿瘤活性，并通过抗原呈递激活T细胞、辨识抗原，最终实现先 天免疫与适应性免疫的系统性协同。 值得关注的是，临床前和早期临床研究显示，HLX701在选择性结合肿瘤CD47的同时 ，与红细胞(RBC)等正常细胞上的CD47结合亲和力较低，且不引起RBC凝集、不诱导 巨噬细胞吞噬RBC,因而HLX701在临床上引发贫血和血小板减少等常见副作用的可能 性较低。临床前研究显示，HLX701联合化疗、免疫检查点抑制剂、表皮生长因子受 体抑制剂及抗血管生成药物等在结直肠癌、胃癌、乳腺癌、肺癌等动物模型中皆可 产生协同抗肿瘤疗效。目前，HLX701单药剂量递增的I期临床研究正在中美同步开 展，其联合不同药物的剂量递增及剂量扩展的Ib/IIa期临床研究也已在中国启动。 复宏汉霖深耕肿瘤免疫治疗领域，已前瞻性布局了包括H药汉斯状(斯鲁利单抗)、 抗PD-L1ADC HLX43等多款具有广谱治疗潜力的创新分子。目前，H药作为全球首个 获批一线治疗小细胞肺癌(SCLC)的抗PD-1单抗，同时是全球首个且唯一胃癌围手术 期III期注册研究成功的抗PD-1单抗，已在中国、德国、英国、印度、新加坡等40 多个国家和地区获批上市。HLX43为潜在同类最优(best-in-class)的创新型PD-L1A DC，兼具免疫检查点阻断(IO)与载荷细胞毒性(ADC)的双重疗效，在非小细胞肺癌( NSCLC)、宫颈癌、食管鳞癌等实体瘤中展现出令人鼓舞的安全性和初步疗效，并在 更多实体瘤中陆续验证。作为复宏汉霖肿瘤免疫管线的重要组成，HLX701差异化的 分子设计有望带来更好的安全性特征，与复宏汉霖现有管线形成深度协同，为新一 代肿瘤免疫治疗方案开辟路径。 未来，复宏汉霖将持续聚焦未满足的临床需求，立足于公司在抗体领域的累积优势 ，不断扩充创新潜力靶点，积极探索前沿技术与疗法，加强优质创新资产的合作， 为全球患者带来更多高质量、可负担的创新治疗方案。 关于HLX701-CRC201 本研究为一项在既往接受过化疗的复发性、不可切除或转移性RAS/BRAF野生型结直 肠癌患者中，比较HLX701联合西妥昔单抗和化疗(FOLFOX/FOLFIRI)对比安慰剂联合 西妥昔单抗和化疗(FOLFOX/FOLFIRI)的1b/2期临床研究。该研究包括三个阶段：第 一阶段为安全导入期，采用3+3剂量递增设计，设5mg/kg至18mg/kg共4个剂量组， 受试者将接受不同剂量的HLX701联合西妥昔单抗和化疗(FOLFOX/FOLFIRI)进行治疗 ，每周一次静脉给药；第二阶段为剂量扩展期，设8mg/kg至18mg/kg共3个剂量组， 每周一次静脉给药，旨在评价不同剂量水平HLX701联合西妥昔单抗和化疗(FOLFOX/ FOLFIRI)的临床疗效和安全性；第三阶段为随机、双盲、多中心研究，对比HLX701 或安慰剂联合西妥昔单抗和化疗的疗效和安全性。 本研究第一阶段的主要终点为评估剂量限制毒性(DLT)的发生比例，次要终点为不 良事件等安全性指标、客观缓解率(ORR)和疾病控制率(DCR)等疗效指标、PK参数、 免疫原性等；第二阶段主要终点为探索2期推荐剂量(RP2D)、独立影像评估委员会( BICR)评估的ORR和无进展生存期(PFS)；第三阶段主要终点为BICR评估的ORR、PFS ；第二和第三阶段的次要终点包括不良事件等安全性指标、总生存期(OS)、研究者 评估的ORR、PFS等疗效指标、PK参数和免疫原性等，同时将探索生物标志物与疗效 的相关性。 关于复宏汉霖 复宏汉霖(2696.HK)是一家国际化创新生物制药企业，致力于为全球患者提供高品 质、可负担的生物药，产品覆盖肿瘤、自身免疫疾并眼科疾病等领域。自2010年成 立以来，公司已构建涵盖全球研发、临床、注册、生产及商业化的全产业链平台， 拥有全球员工近4,000人，并在中国、美国和日本等多地设有运营及分支机构。依 托生物类似药形成的稳健现金流反哺创新研发，复宏汉霖正稳步迈入“全球化2.0 ”阶段，持续打造可复制、可持续的全球增长模式。截至2026年初，公司共有10款 产品在全球60个国家和地区获批上市，其中7款已在中国获批。在欧美主流生物药 市场，复宏汉霖亦取得多项里程碑式突破，已有4款产品获得美国FDA批准、4款产 品获得欧盟EC批准，充分体现了公司在研发体系、质量管理及生产能力方面已全面 对标国际最高标准。 在创新驱动方面，复宏汉霖依托上海、美国等多地协同布局的研发体系，构建了多 元化、平台化的创新技术矩阵，覆盖免疫检查点抑制剂、免疫细胞衔接器(包括多 特异性TCE)、抗体偶联药物(ADC)以及AI驱动的早期研发平台等前沿方向。目前， 公司拥有50余项处于早期阶段的创新资产，其中约70%具备同类最佳(Best-in-Clas s)潜力，并在全球同步推进30余项临床研究。核心产品H药汉斯状(斯鲁利单抗，欧 洲商品名：Hetronifly)作为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，正 加速全球布局，已在全球40余个市场获批上市；同时，多款潜力创新资产，包括PD -L1ADC HLX43及新表位HER2单抗HLX22正全面推进全球关键性临床研究。依托通过 中、欧、美三地GMP认证的生产体系，复宏汉霖已建成总产能达84,000升的生物药 生产平台，形成覆盖全球六大洲的稳定供应网络。未来，复宏汉霖将始终坚持以患 者为中心，聚焦未满足的临床需求，持续推动创新成果向临床价值与患者可及转化 ，在全球生物医药创新生态中创造长期而稳健的价值。 First Patient Dosed in a Phase1b/2Clinical Trial of HLX701Combination T herapy in Advanced Colorectal Cancer March 26,2026,Shanghai Henlius Biot ech,Inc.(2696.HK)today announced that the first patient has been dosed i n a Phase1b/2trial(HLX701-CRC201)evaluating its novel recombinant human SIRPα-Fc fusion protein,HLX701,in combination with cetuximab and chemot herapy in patients with advanced RAS/BRAF wild-type metastatic colorecta l cancer(mCRC). Colorectal cancer is a highly prevalent malignancy both in China and gl obally.In2022,there were approximately1.926million new cases and904,000d eaths worldwide,with China accounting for517,000new cases and240,000deat hs,ranking second in incidence and fourth in mortality among all cancers 1-2.Standard first-and second-line treatments for advanced/metastatic co lorectal cancer typically include fluoropyrimidine-based chemotherapy co mbined with either anti-angiogenic agents(anti-VEGF targeted therapy,e.g .,bevacizumab)or anti-EGFR targeted therapy.Specifically,for patients wi th RAS/BRAF wild-type mCRC,cetuximab(anti-EGFR targeted agents)plus chem otherapy is one of the recommended first-line regimens.However,as the di sease progresses to later lines,treatment options become more limited an d increasingly depend on prior treatment response,performance status(e.g .,ECOG score),and specific molecular subtypes3-4.Later-line options5-7su ch as regorafenib,fruquintinib,and TAS-102offer limited clinical overall benefits,underscoring a critical unmet need for more effective and comb ination-ready therapies.Immunotherapies targeting the CD47-SIRPαsignali ng pathway have entered clinical trials in colorectal cancer and other s olid and hematologic malignancies.Notably,its combination regimens have shown potential synergy in specific molecular subtypes of cancer8-9.As n ext-generation CD47-SIRPα-targeted therapies continue to advance,furthe r clinical validation is warranted to establish their efficacy and optim al combination strategies. HLX701is a next-generation SIRPα-Fc fusion protein in-licensed from FB D Biologics Limited(“FBD”),a subsidiary of HanchorBio,and is being adv anced under a collaboration agreement between the parties.This molecule is an engineered fusion protein combining a human SIRPαimmunoglobulin(I gV)domain with the crystallizable fragment(Fc)region of human Immunoglob ulin G4(IgG4).It binds to CD47on tumor cells with high affinity,effectiv ely blocking the inhibitory CD47"don't eat me"signaling,thereby promotin g macrophage-mediated phagocytosis of tumor cells and enhancing anti-tum or activity.It further activates T cells via antigen presentation,ultima tely achieving synergistic engagement of both innate and adaptive immuni ty. Notably,nonclinical and early clinical data suggest that HLX701,while b inding selectively and with high affinity to tumor CD47,exhibits minimal binding to CD47on normal cells such as red blood cells(RBCs).Consequent ly,it neither induces RBC agglutination nor promotes macrophage-mediated RBC phagocytosis,thereby demonstrating a lower potential to cause commo n hematological adverse events,including anemia and thrombocytopenia,in clinical settings.In animal models,HLX701has shown additive or synergist ic antitumor activity when combined with chemotherapy,immune checkpoint inhibitors,epidermal growth factor receptor(EGFR)inhibitors,or anti-angi ogenic agents across multiple tumor models,including colorectal,gastric, breast,and lung cancers.Currently,a Phase1dose-escalation study of HLX70 1monotherapy is ongoing in both China and the U.S.,and Ib/2a studies of HLX701in combination with various agents are also underway in China. Among them,the company's self-developed anti-PD-1monoclonal antibody(mA b),serplulimab,is the world's first anti-PD-1mAb approved for first-line treatment of small cell lung cancer(SCLC),and the first and only anti-P D-1with positive results from a phase3registrational trial in the periop erative treatment of gastric cancer(GC).To date,it has been approved in over40countries and regions,including China,Germany,the UK,India,and Sin gapore.HLX43is a potential best-in-class pan-tumor ADC targeting PD-L1th at integrates dual mechanisms:immune checkpoint blockade and payload-med iated cytotoxicity.It has shown broad therapeutic potential in preclinic al and early clinical studies,with an encouraging safety profile and pre liminary efficacy in non-small cell lung cancer(NSCLC),cervical cancer(C C),and esophageal squamous cell carcinoma(ESCC)，with ongoing validation in other solid tumors such as cervical cancer(CC)and esophageal squamou s cell carcinoma(ESCC).HLX701represents a key asset in Henlius'immuno-on cology pipeline.Its differentiated molecular design holds promise for an improved safety profile and the potential to synergize deeply with Henl ius'existing pipeline assets,thereby paving the way for next-generation immuno-oncology treatment strategies. Guided by unmet clinical needs and its antibody platform strength,Henli us will pursue novel targets with high potential,actively explore fronti er technologies,and seek partnerships for premium,innovative assets to b ring more quality,affordable treatment options to patients worldwide. About HLX701-CRC201 This Phase1b/2clinical study compares HLX701in combination with cetuxim ab and chemotherapy(FOLFOX/FOLFIRI)versus placebo in combination with ce tuximab and chemotherapy(FOLFOX/FOLFIRI)in patients with recurrent,unres ectable,or metastatic RAS/BRAF wild-type colorectal cancer who have prev iously received chemotherapy.This study consists of three stages:In Stag e1(safety run-in),a3+3dose-escalation design is used,with a total of4dos e levels ranging from5mg/kg to18mg/kg.Subjects will be treated with HLX7 01in combination with cetuximab and chemotherapy at different dose level s,with intravenous administration once per week.In Stage2,there are3dose groups ranging from8mg/kg to18mg/kg,administered once weekly by intrave nous infusion,to evaluate the clinical efficacy and safety of HLX701in c ombination with cetuximab and chemotherapy at different dose levels.Stag e3is a randomized,double-blind,multi-center study comparing the efficacy and safety of HLX701or placebo in combination with cetuximab and chemot herapy.The primary endpoint for Stage1is the proportion of dose-limiting toxicities(DLTs),while secondary endpoints include safety indicators su ch as adverse events,efficacy indicators such as objective response rate (ORR)and disease control rate(DCR),pharmacokinetic(PK)parameters,and imm unogenicity.The primary endpoints for Stage2are determination of the rec ommended Phase2dose(RP2D)and the ORR and progression-free survival(PFS)a s assessed by Blinded Independent Central Review(BICR).The primary endpo ints for Stage3are the ORR and PFS as assessed by BICR.The secondary end points of Stage2and Stage3include safety indicators such as adverse even ts,efficacy endpoints(e.g.,ORR and PFS assessed by investigators,overall survival[OS]),PK parameters,and immunogenicity,as well as the explorati on of the association between biomarkers and efficacy. About Henlius Shanghai Henlius Biotech,Inc.(2696.HK)is a global,innovat ion-driven biopharmaceutical company committed to delivering high-qualit y,affordable biologic therapies to patients worldwide.The Company focuse s on major disease areas including oncology,autoimmune diseases,and opht halmic diseases.Founded in2010,Henlius has established an integrated,end -to-end biopharmaceutical platform encompassing global R&D,clinical oper ations,regulatory affairs,manufacturing,and commercialisation.The Compan y employs nearly4,000people globally and operates across multiple region s,including China,the United States,and Japan.Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation,Henl ius is steadily advancing into its“Globalisation2.0”phase,building a s calable and sustainable global growth model.As of early2026,Henlius has achieved regulatory approvals for10products across60countries and region s worldwide,including seven approvals in China.The Company has also reac hed multiple milestones in major biopharmaceutical markets,with four pro ducts approved by the U.S.Food and Drug Administration(FDA)and four prod ucts approved by the European Commission(EC),reflecting its globally ali gned R&D capabilities,quality systems,and manufacturing standards. Driven by innovation,Henlius has built a diversified,platform-based tec hnology ecosystem through coordinated R&D efforts across Shanghai,the Un ited States,and other regions.Its innovation platforms span immune check point inhibitors,immune cell engager technologies(including multispecifi c T cell engagers),antibody-drug conjugates(ADCs),and AI-enabled early d iscovery platforms.The Company currently has more than50early-stage inno vative assets,approximately70%of which are expected to be best-in-class, with over30clinical trials ongoing globally.Henlius’core product,serplu limab(trade name:Hetronifly in Europe),is the world’s first anti–PD-1m Ab approved for first-line treatment of small cell lung cancer and has b een approved in more than40markets worldwide with an accelerated globali sation process.In parallel,multiple high-potential innovative assets—in cluding the PD-L1ADC HLX43and the novel epitope anti-HER2mAb HLX22—are advancing through global pivotal clinical development.Supported by a bio logics manufacturing network with a total capacity of84,000L and GMP cer tifications from regulatory authorities in China,Europe,and the United S tates,Henlius has established a stable global supply system serving six continents.Guided by a patient-centred mission,Henlius remains focused o n addressing unmet medical needs and translating scientific innovation i nto meaningful clinical value and patient access,contributing sustainabl y to the global biopharmaceutical ecosystem. To learn more about Henlius,visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/hen lius/. References 1.Bray F,et al.Global cancer statistics2022:GLOBOCAN estimates of incide nce and mortality worldwide for36cancers in185countries.CA Cancer J Clin .2024;74(3):229-263. 2.Han B,et al.Cancer incidence and mortality in China,2022.J Natl Cancer Cent.2024Feb2;4(1):47-53. 3.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines):Colon C ancer version5.2025 4.2025CSCO结直肠癌诊疗指南 5.Grothey A,et al;CORRECT Study Group.Regorafenib monotherapy for previo usly treated metastatic colorectal cancer(CORRECT):an international,mult icentre,randomised,placebo-controlled,phase3trial.Lancet.2013Jan26;381(9 863):303-12. 6.Mayer R J,et al.Randomized Trial of TAS-102for Refractory Metastatic C olorectal Cancer[J].New England Journal of Medicine,2015,372(20):1909-19 19. 7.Li J,et al.Effect of Fruquintinib vs Placebo on Overall Survival in Pa tients with Previously Treated Metastatic Colorectal Cancer:The FRESCO R andomized Clinical Trial.JAMA.2018;319(24):2486–2496. 8.Eng C,et al.A Phase1b/2Study of the Anti-CD47Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.Targ et Oncol.2025May;20(3):519-530. 9.Lentz RW,et al.Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47Blockade Combination in Refractory Microsatellite-Stable Meta static Colorectal Cancer.Cancer Res Commun.2025Nov1;5(11):2039-2052. 【3.最新异动】 ┌──────┬───────────┬───────┬───────┐ ｜ 异动时间 ｜ 2022-09-05 ｜ 成交量(万股) ｜ 5538.424 ｜ ├──────┼───────────┼───────┼───────┤ ｜ 异动类型 ｜ 日跌幅偏离值达7% ｜成交金额(万元)｜ 202908.810 ｜ ├──────┴───────────┴───────┴───────┤ ｜ 卖出金额排名前5名营业部 ｜ ├──────────────────┬───────┬───────┤ ｜ 营业部名称 ｜ 买入金额(元) ｜ 卖出金额(元) ｜ ├──────────────────┼───────┼───────┤ ｜沪股通专用 ｜ 0.00｜ 104568712.44｜ ｜机构专用 ｜ 0.00｜ 77999788.62｜ ｜招商证券股份有限公司北京建国路证券营｜ 0.00｜ 41237672.00｜ ｜业部 ｜ ｜ ｜ ｜招商证券股份有限公司上海翔殷路证券营｜ 0.00｜ 29884759.00｜ ｜业部 ｜ ｜ ｜ ｜机构专用 ｜ 0.00｜ 28046464.81｜ ├──────────────────┴───────┴───────┤ ｜ 买入金额排名前5名营业部 ｜ ├──────────────────┬───────┬───────┤ ｜ 营业部名称 ｜ 买入金额(元) ｜ 卖出金额(元) ｜ ├──────────────────┼───────┼───────┤ ｜申万宏源证券有限公司上海静安区延长中｜ 55595630.00｜ 0.00｜ ｜路证券营业部 ｜ ｜ ｜ ｜沪股通专用 ｜ 38892558.32｜ 0.00｜ ｜光大证券股份有限公司宁波钱湖北路证券｜ 22963630.61｜ 0.00｜ ｜营业部 ｜ ｜ ｜ ｜华福证券有限责任公司上海遵义路证券营｜ 18196227.00｜ 0.00｜ ｜业部 ｜ ｜ ｜ ｜东方财富证券股份有限公司拉萨东环路第｜ 17817409.00｜ 0.00｜ ｜一证券营业部 ｜ ｜ ｜ └──────────────────┴───────┴───────┘ 【4.最新运作】 【公告日期】2026-03-25【类别】关联交易 【简介】公司与关联方在2025年发生销售原材料,提供劳务,出租等日常关联交易预 计33,100万元。20250412：本次预计与关联方上海复健股权投资基金管理有限公司 预计发生接受关联方劳务,向关联方出租房屋及提供物业服务,向关联方提供劳务日 常关联交易，预计新增5740万元。20251029：本次预计新增关联交易额度2,000万 元。20251129：1-9月实际发生金额(未经审计)13,265万元20260325：披露2025年 日常关联交易执行情况。 【公告日期】2025-11-29【类别】关联交易 【简介】由于本公司与复星国际于2023年12月15日签订的《租赁框架协议》(包括 涉及房屋承租、出租业务的协议各1份)及《产品和服务互供框架协议》(期限均为2 024年1月1日至2024年12月31日)即将到期,根据业务开展需要,2024年12月11日,本 公司与复星国际续签框架协议(即《租赁框架协议》及《产品和服务互供框架协议 》,下同),协议期限自2025年1月1日至2025年12月31日。20251129：根据业务开展 需要，2025年11月28日，本公司与复星国际续签框架协议（即《租赁框架协议》及 《产品和服务互供框架协议》，下同），协议期限自2026年1月1日至2026年12月31 日。 【公告日期】2025-11-29【类别】关联交易 【简介】公司与关联方在2026年发生销售原材料,提供劳务,出租等日常关联交易预 计36,650万元。 【公告日期】2010-03-25【类别】资产交易 【简介】复星平耀与复星创投于2009年10月27日签署《出资份额转让协议》，复星 平耀向复星创投转让所持有的谱润合伙99%的出资份额（即其在谱润合伙首期出资 额中所对应中的财产份额人民币5,940万元），转让对价为人民币5,940万元。 【公告日期】2009-11-19【类别】资产交易 【简介】复星平耀与复星创投于2009 年10 月27 日签署《出资份额转让协议》， 复星平耀向复星创投转让所持有的谱润合伙99%的出资份额（即其在谱润合伙首期 出资额中所对应中的财产份额人民币5,940 万元），转让对价为人民币5,940 万元 。 【公告日期】2004-04-24【类别】资产交易 【简介】为优化资源配置，2003 年11 月28 日，公司与复地(集团)股份有限公司 签订房产转让合同，公司将所拥有的位于上海市曹杨路510 号九楼510m2 的房产转 让给复地集团，转让房产帐面净值为人民币1,833,832.58 元。参照市价，双方协 商确定的转让价为人民币2,550,000.00 元，扣除缴纳的相关税金后，公司取得房 产转让收益574,642.42 元。公司与复地集团的母公司同为上海复星高科技（集团 ）有限公司，本次转让构成关联交易。 免责声明：本信息由本站提供，仅供参考，本站力求 但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为 准，本站不对因该资料全部或部分内容而引致的盈亏承担任何责任。 用户个人对服务的使用承担风险。本站对此不作任何类型的担保。本站不担保服 务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出 错发生都不作担保。本站对在本站上得到的任何信息服务或交易进程不作担保。 本站提供的包括本站理财的所有文章，数据，不构成任何的投资建议，用户查看 或依据这些内容所进行的任何行为造成的风险和结果自行负责，与本站无关。
